1 Lew

## PATENT--NO FEE



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

ZAIJIE WANG

Serial No.: 10/769,536

Filed: January 30, 2004

For: METHOD AND COMPOSITION FOR POTENTIATING AN OPIATE ANALGESIC

Attorney Docket No. 27611/38972A

Group Art Unit: 1614

Examiner: Unassigned

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage, as first class mail, in an envelope addressed to:
Commissioner for Patents P.O. Box 1450
Alexandria, VA 22313-1450

Dated: December 2, 2004

James J. Napoli

Registration No. 32,361 Attorney for Applicants

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

)

)

)

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to his duty of disclosure under 37 C.F.R. §1.56, applicant hereby brings to the examiner's attention patent documents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicant encloses a completed Form PTO-1449 listing the possible pertinent patents and publications and a copy of each publication and non-U.S. patent document.

This Supplemental Information Disclosure
Statement is submitted more than three months after the filing date of the above-identified application, and,

to applicants' knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. §1.97(b), this Supplemental Information Disclosure Statement shall be considered by the Patent Office.

In addition, if a first Office Action has been mailed, each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement (37 C.F.R. \$1.97(e)(1)). Accordingly, no fee as set forth in 37 C.F.R. \$1.17(p) is due.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

A copy of the International Search Report is enclosed for the convenience of the examiner and to complete the file.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

By

James J. Napoli

(Registration No. 32,361) Attorneys for Applicants 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606 (312) 474-6300

Chicago, Illinois December 2, 2004

		101	PE		
For	m 1449PTO		6 2004 3	Complete if Known	
		DEC 0	8 2004 E	Application Number	10/769,536
11	VFORMATI	DI KAKO	SCL@SURE	Filing Date	January 30, 2004
l s	STATEMEN	TBYTH	SCLOSURE	First Named Inventor	Zaijie Wang
(use as many sheets as necessary)				Group Art Unit	1614
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	27611/38972A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY		
		5,866,154	02/02/1999		
		6,432,652	08/13/2002		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY		
		0 608 893 (EPO)	08/03/1994		
		0 911 039 (EPO)	04/28/1999		

OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		G-H. Fan et al., Molecular Pharmacology, 56:39-45 (1999).		
		P. Nitescu et al., <i>Eur. J. Pain, 13</i> , 3, 76-88 (1992).		
		L. Lou et al., Molecular Pharmacology, 55:557-563 (1999).		
		·		
-				
<u> </u>				
	<b>-</b>			

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.